Floatz logo

INTERLEUKIN-21

Lymphoma, Hodgkins

National Cancer Institute (NCI)protein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Lymphoma, Hodgkins cohort.

Asset / SponsorPhaseRating
Rhil-7
National Cancer Institute (NCI)
Phase 1CC

Same molecule, other indications

INTERLEUKIN-21 is also rated in:

Lymphoma, Non-hodgkinsDormant
CC
Indicative ·
47 / 100
View asset →
Leukemia, B-cellDormant
CC
Indicative ·
46 / 100
View asset →
Lymphoma, B-CellDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →